Mark McDonough will become CEO of CombiMatrix when Judd Jessup retires on March 15, the molecular diagnostics firm said last week. McDonough is currently the chief commercial officer at CombiMatrix. Before joining the firm last year, he was vice president of sales, customer service, and training at Pathwork Diagnostics, another molecular diagnostics firm that specializes in microarray-based tests.
CombiMatrix appointed Jessup CEO in 2010. In recent years, he has refocused the company on prenatal and pediatric microarray-based cytogenetic testing. In a statement, Jessup portrayed his role at CombiMatrix as leading its transition to a "pure-play diagnostics lab." Calling that transition complete, he said that the company will be in "very capable hands" under McDonough's leadership.